Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. CMG
8. KLAC
9. BIIB
10. ETSY

Go back to Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

Cyclacel Pharma (CYCC) Halted on LUDP

April 4, 2017 10:25 AM EDT

Cyclacel Pharma (NASDAQ: CYCC) Halted on LUDP

... More

Cyclacel Pharma (CYCC) Continues Monday's Surge Following Preclinical Anti-Cancer Data; Gains Another 40%

April 4, 2017 8:13 AM EDT

Cyclacel Pharma (NASDAQ: CYCC) adds to Monday's 75% gains after the company announced over the weekend the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor, as a targeted anti-cancer agent.

Shares are up another 40% in pre-open trade to $9.00.

... More

Cyclacel Pharma (CYCC) Surges Following Preclinical Data on CYC065

April 3, 2017 10:09 AM EDT

Cyclacel Pharma (NASDAQ: CYCC) adds to gains following earlier volatility trading halt and news over the weekend from AACR. Shares are up 54%

Cyclacel Pharma announced the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK)... More